Home・Aktien・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Geschlossen

14.31 -6.84

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

14.8

Max

15.7

Schlüsselkennzahlen
By Trading Economics
Einkommen	-4.3M -18M
EPS	-0.19
Angestellte	37
EBITDA	-5.3M -17M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+98.92% upside

Dividenden
By Acuity
Nächstes Ergebnis	3. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	130M 1.3B
Vorheriger Eröffnungskurs	21.15
Vorheriger Schlusskurs	14.31

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

19. Aug. 2026, 23:56 UTC

News

Wayfair shares rise in after-market hours after Rosenblatt analyst Scott Devitt initiated coverage with a Buy rating and a price target of $125.00.

19. Aug. 2026, 23:56 UTC

Peloton Interactive Inc shares are lower in after-market hours with no specific news to explain the decline. The stock remains below its 20-day moving average.

19. Aug. 2026, 23:56 UTC

Shares of Nova Ltd. rose in after-market trading, despite earlier fluctuations and remaining below its 20-day moving average.

19. Aug. 2026, 23:56 UTC

Certara Inc. shares are lower in after-hours trading, showing slight declines since Wednesday's close while remaining above the 20-day moving average.

19. Aug. 2026, 23:56 UTC

CareDx Inc shares are higher in after-market hours, remaining above their 20-day moving average. No specific news was identified to explain the movement.

19. Aug. 2026, 23:56 UTC

Correlated Moves

Pinnacle West Capital shares are modestly higher in after-market trading, tracking a similar rise in PG&E Corp, indicating potential market correlation.

19. Aug. 2026, 23:56 UTC

Pentair PLC shares are lower in after-market trading, reflecting routine activity and slight declines since Wednesday's close. The price remains near the one-month midpoint.

19. Aug. 2026, 23:56 UTC

Best Buy Co Inc shares are higher in after-market trading, fluctuating slightly while remaining above their 20-day moving average. No specific news was identified.

19. Aug. 2026, 23:56 UTC

Charles River Laboratories shares are higher in after-market trading, reaching a notable increase since Wednesday's close and positioning near the upper end of its one-month range.

19. Aug. 2026, 23:56 UTC

Quest Diagnostics Inc shares are higher in after-market hours, continuing a trend of four consecutive sessions finishing above their 20-day moving average.

19. Aug. 2026, 23:56 UTC

GSI Technology Inc's shares are higher in after-market trading, despite a recent decline and ongoing weakness below the 20-day moving average.

19. Aug. 2026, 23:56 UTC

Invesco DB Agriculture Fund is higher in after-market trading, reflecting a notable upward move since Wednesday's close and trading near its one-month range.

19. Aug. 2026, 23:56 UTC

CF Industries remains roughly flat in after-market hours, trading near the middle of its one-month range and slightly below its 20-day moving average.

19. Aug. 2026, 23:56 UTC

Apollo Global Management shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

19. Aug. 2026, 23:56 UTC

Ares Capital Corp shares are higher in after-market trading, reflecting a generally positive performance backdrop. The stock remains above its 20-day moving average.

19. Aug. 2026, 23:56 UTC

Huntington Bancshares Inc shares are higher in after-market trading, despite no specific news. The stock remains below its 20-day moving average.

19. Aug. 2026, 23:56 UTC

FactSet Research Systems is trading lower in after-market hours, reflecting a decline since Wednesday's close, with no specific news identified for the movement.

19. Aug. 2026, 23:56 UTC

Shoals Technologies Group Inc is trading lower in after-market hours, continuing a downward trend without any specific news to explain the movement.

19. Aug. 2026, 23:56 UTC

News

Social Media

Cogent Communications is facing a class action lawsuit over alleged false statements, contributing to a decline in shares during after-market hours.

19. Aug. 2026, 23:52 UTC

News

Correlated Moves

Cohen & Steers Inc. shares are lower in after-market trading, continuing a trend of five consecutive daily declines. The fund declared a monthly dividend of $0.126 per share.

19. Aug. 2026, 23:52 UTC

Progressive Corp shares are higher in after-market hours, reflecting a modest gain since Wednesday's close. The stock remains above its 20-day moving average.

19. Aug. 2026, 23:51 UTC

Doximity Inc shares are lower in after-market trading, with no specific news identified for the decline. The stock remains above its 20-day moving average.

19. Aug. 2026, 23:51 UTC

Peabody Energy shares are lower in after-market trading, reversing an earlier gain. The stock remains above its 20-day moving average.

19. Aug. 2026, 23:51 UTC

Patria Investments Ltd is trading higher in after-market hours, reaching 2.45% above Wednesday's close and showing strong momentum above its 20-day moving average.

19. Aug. 2026, 23:51 UTC

Workday Inc. shares are higher in after-market trading, continuing a month-long upward trend and remaining above the 20-day moving average.

19. Aug. 2026, 23:51 UTC

Pinterest Inc. shares moved lower in after-market trading, retracing earlier gains and remaining below their 20-day moving average.

19. Aug. 2026, 23:51 UTC

Kilroy Realty Corp shares are lower in after-market trading, continuing a decline since Wednesday's close and positioned below its 20-day moving average.

19. Aug. 2026, 23:51 UTC

Take-Two Interactive shares are higher in after-market hours, recovering from earlier lows. No specific news was identified to explain the price movement.

19. Aug. 2026, 23:51 UTC

News

Biomarin Pharmaceutical Inc shares are lower in after-market hours amid a broader Biotechnology sector decline, despite a recent $275 million acquisition of Alesta Therapeutics.

19. Aug. 2026, 23:51 UTC

Mixed trading in European equities as Eurozone inflation rises to 2.9% and German Bund yields hit a 12-year high amid geopolitical tensions.

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

98.92% Vorteil

12-Monats-Prognose

Durchschnitt 29.5 USD 98.92%

Hoch 33 USD

Tief 27 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Corvus Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.